UCLA Campus    |   UCLA Health    |   School of Medicine Translate:
UCLA Health It Begins With U

UCLA Rheumatology

Print
Email
Share

Research and Clinical Trials

UCLA Division of Rheumatology conducts cutting-edge biomedical and health-related research studies that include both interventional and observational studies. Our clinical studies are sponsored/funded by National Institute of Health (NIH), pharmaceutical companies, and/or non-profit medical institutions/organizations.

Treatment/Interventional studies are those in which the research subjects are assigned to a treatment or intervention and their outcomes are measured.

Observational studies are those in which individuals are observed and their outcomes are measured by the study investigators.

Current Clinical Trials

Rheumatoid Arthritis
Cholesterol
Lupus
Scleroderma
Vasculitis

If you would like to get more information on any studies please call us at (310) 825-0096 or email rheumresearch@mednet.ucla.edu.

If you are interested in finding out more information of a particular study, please contact the study personnel.

Study Type

Title of Study

Rheumatoid Arthritis
Treatment/
Interventional
*Multiple studies

Principal Investigators
Christina Charles-Schoeman, MD; Veena Ranganath, MD

For more information contact 310-825-0096 

Treatment/Interventional

Dietary Intervention on Rheumatoid Arthritis Assessed by Ultrasound in over weight patients

Status: Recruiting

Principal Investigator Veena K. Ranganath, MD, MS

For more information, please contact (310) 825-9956

Treatment/Interventional

Musculoskeletal Ultrasound Predicting Therapeutic Response in Tofacitinib in Rheumatoid Arthritis Patients

Status: Recruiting 

Principal Investigator Veena K. Ranganath, MD, MS

For more information, contact (310) 825-9956

Observational

HDL (Carotid Study): Evaluation of HDL function in patients with and without Rheumatic Disease

Status: Open for Enrollment

Principal Investigator Christina Charles, MD

For more information, contact Jeraldine Guzman (310) 825-4744

Treatment

AMGEN 20130207: A Multicenter Double-blind, Randomized Controlled study of Etanercept and Methotrexate in cobination or as Monotherapy in subjects with Psoriatic Arthritis

Status: Open for Enrollment

Principal Investigator Suzanne Kafaja, MD

For more information, contact Jeraldine Guzman (310) 825-4744

Cholesterol
Observational HDL Function in Patients With and Without Rheumatic Disease (Investigatory)

Principal Investigators
Christina Charles-Schoeman, MD

For more information, contact Jeraldine Guzman 
(310) 825-4744
Lupus
Treatment Efficacy of Abatacept (Orencia®) in inflammatory Polyarthritis of Systemic Lupus Erythematosus (SLE) 

Status: Recruiting

Principal Investigator
Bevra Hahn, MD

For more information contact
Mia Vasquez-Gutierrez (310)825-6461

Treatment

Rituximab plus Cyclophosphamide followed by Belimumab for the treatment of Lupus Nephritis (CALIBRATE)

Status: Recruiting

Principal Investigators
Maureen McMahon, MD

For more information contact
Mia Vasquez-Gutierrez
310-825-6461

Treatment

Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (STOP RA)

Status: Recruiting

Principal Investigators
Maureen McMahon, MD

For more information contact
Mia Vasquez-Gutierrez
310-825-6461

Treatment

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with active Proliferative Lupus Nephritis

Status: Recruiting

Principal Investigator
Jennifer Grossman, MD 

For more information, contact Mia Vasquez-Gutierrez (310) 825-6461
Treatment

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating Efficacy and Safety of Anifrolumab in Adult subjects with Active Systemic Lupus Erythematosus (SLE)

Status: Recruiting

Principal Investigator Jennifer Grossman, MD

For more information, contact Mia Vasquez-Gutierrez (310) 825-6461

Observational Biomarkers in Lupus

Status: Recruiting
Principal Investigator
Ram Raj Singh, MD

For more information contact
Ram Raj Singh, MD
Observational The Role of Gender Factors in Lupus and Autoimmunity

Status: Recruiting
Principal Investigator
Ram Raj Singh, MD

For more information contact
Ram Raj Singh, MD

Observational Autoimmunity Characteristics in Patients with Systemic Lupus Erythematosus versus Health Controals 

Status: Recruiting

Principal Investigator
Jennifer King, MD 

For more information contact
Jennifer King, MD 

Observational Observational, Mechanisms of Inflammation and Immune Response in Skin Dermatoses.

Status: Recruiting

Principal Investigator
Jennifer King, MD

For more information contact
Jennifer King, MD 

Treatment/
Interventional
*Multiple studies

Status: Recruiting
Principal Investigators
Jennifer Grossman, MD; Maureen McMahon, MD

For more information, contact Mia Vasquez-Gutierrez (310) 825-6461

     
Scleroderma
Treatment/
Interventional
*Multiple studies Principal Investigator
TBD
Treatment

ROCHE WA29767: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab versus Placebo in Patients with Systemic Sclerosis

Status:  Open for Enrollment

Principal Investigators
Suzanne Kafaja, MD

For more information contact
Nashla Barroso
(310) 825-9682

 

Observational SPIN: The Scleroderma Patient-Centered Intervention Network (SPIN) Cohort 

Status: Open for Enrollment

 

Principal Investigator
Suzanne Kafaja, MD

For more information, contact Nashla Barroso (310) 825-9682

Observational

Blood and Skin Biopsy Donation: A research study to define the differences in Immune Responses in skin from patients with an autoimmune or inflammatory condition

Status:  Open for Enrollment

Principal Investigator
Suzanne Kafaja, MD

For more information, contact
Nashla Barroso
(310) 825-9682

Treatment

Bayer 16277: A Randomized, Double-Blind, Placebo-Controlled Phase II study to investigate the Efficacy and Safety of Riociguat in patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Status: Open for Enrollment

Principal Investigators
Suzanne Kafaja, MD

For more information, contact Nashla Barroso (310) 825-9682

Treatment

ASSETT IM101-344: A phase II study to evaluate subcutaneous Abatacept vs. Placebo in diffuse cutaneous systemic sclerosis--a double-blind, placebo-controlled, randomized controlled trial

Status: Open for Enrollment

Principal Investigator Suzanne Kafaja, MD

For more information, contact Jeraldine Guzman (310) 825-4744

Treatment

Scleroderma Treatment with Autologus Transplant (STAT) Study: A phase II multi-center study of high-dose Cyclophosphamide and Antithymocyte Globulin followed by Autologus Hematopoietic Cell Transplant with post transplant maintenance for the treatment of Systemic Sclerosis

Status: Open for Enrollment

Principal Investigator Suzanne Kafaja, MD

For more information, contact Jeraldine Guzman (310) 825-4744

Other PHAROS: Outcome Studies in Systemic Sclerosis: A Prospective Database of Echocardiograms and PFTs on Patients with Limited Scleroderma (Standard of Care)

Status: Recruiting

Principal Investigators
Philip Clements, MD

For more information, contact Nashla Barroso (310) 825-9682

Observational

Quality od Life: Quality of Life of people with scleroderma: Health values and minimally important differences of people with scleroderma

Status: Open for Enrollment

Principal Investigator Suzanne Kafaja, MD

For more information, contact Nashla Barroso (310) 825-9682

Vasculitis
Treatment A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis"
This is a phase 3 clinical trial evaluating Sirukumab (a monoclonal antibody against interleukin 6) in patients with giant cell arteritis.
Status: Recruiting
Principal Investigator
Tanaz Kermani, MD

For more information contact
310-825-0096

UCLA Rated One of the Top Hospitals in the Nation